Anti Inflammatory News and Research

RSS
New Penn study questions relevance of fish oil-derived SPMs and their anti-inflammatory effects in humans

New Penn study questions relevance of fish oil-derived SPMs and their anti-inflammatory effects in humans

New research shows promising progress in use of anti-inflammatory cytokine for T1D treatment

New research shows promising progress in use of anti-inflammatory cytokine for T1D treatment

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Moerae announces initiation of second MMI-0100 Phase 1 clinical trial for pulmonary disorders

Biologists identify genetic mechanisms behind anti-inflammatory impact of cortisone

Biologists identify genetic mechanisms behind anti-inflammatory impact of cortisone

Researchers develop dynamic smart drug that targets site-specific inflammation

Researchers develop dynamic smart drug that targets site-specific inflammation

Sulfur dioxide air pollutant can cause adverse effects in asthmatics

Sulfur dioxide air pollutant can cause adverse effects in asthmatics

New study shows cannabinoid cannabidiol can help heal bone fractures

New study shows cannabinoid cannabidiol can help heal bone fractures

Nitric oxide released through nanotechnology may be a new way to treat, prevent acne

Nitric oxide released through nanotechnology may be a new way to treat, prevent acne

Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients

Wayne State researchers explore effects of Tocotrienol-rich fraction from palm oil in ESRD patients

Aspirin may inhibit the growth of mesothelioma, shows study

Aspirin may inhibit the growth of mesothelioma, shows study

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Common arthritis drug could help to treat patients with blood cancers

Common arthritis drug could help to treat patients with blood cancers

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

Dr. Jian-Dong Li receives $1.6 million to develop novel therapeutic targets to treat middle-ear infections

Dr. Jian-Dong Li receives $1.6 million to develop novel therapeutic targets to treat middle-ear infections

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Cell transplantation researchers successfully treat laboratory rats modeled with severe burns

Pioglitazone drug significantly decreases risk of dementia

Pioglitazone drug significantly decreases risk of dementia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.